Source comparison
Thymosin Alpha-1 and Thymalin: Product Comparison
Thymosin Alpha-1 Single 28-amino-acid peptide (3,108 Da) TLR9 activation → NF-κB signaling → IL-2/IL-7 upregulation 1.6mg subcutaneous, twice weekly Toll-like receptor 9 on dendritic cells CD4+/CD8+ TREC counts, serum IL-2 levels Best for cytokine-driven T-cel
This comparison does not assign a generated winner or score.
- Thymosin Alpha-1
- Single 28-amino-acid peptide (3,108 Da)
- TLR9 activation → NF-κB signaling → IL-2/IL-7 upregulation
- 1.6mg subcutaneous, twice weekly
- Toll-like receptor 9 on dendritic cells
- CD4+/CD8+ TREC counts, serum IL-2 levels
- Best for cytokine-driven T-cell expansion; requires pulsatile dosing to maintain receptor engagement
- Thymalin
- Polypeptide mixture (<10 kDa), 30+ distinct fragments
- FOXN1 upregulation in thymic epithelial cells → structural regeneration
- 10mg subcutaneous, daily for 10–20 days
- Thymic epithelial cell nuclear receptors (mechanism partially characterized)
- Thymic cortex/medulla ratio on imaging, epithelial cell markers (cytokeratin 5/8)
- Best for structural thymic restoration; effects persist 10–14 days post-cycle due to gene expression changes
- Stacked Protocol
- Combined administration
- Synergistic: epithelial scaffold + cytokine environment
- Thymalin daily (start day 1), Tα1 twice weekly (start day 3–5)
- Both pathways engaged simultaneously
- TREC counts + thymic epithelial immunohistochemistry
- Maximum thymic output restoration when baseline function >20% of youthful capacity; limited benefit if thymus fully involuted